The ALT-FLOW II trial is currently enrolling up to 100 participants at sites in the United States and Oklahoma Heart Institute is one of those facilities. TULSA, Okla. - Tulsa’s Oklahoma Heart ...
BOSTON, MA—Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and elevated left atrial pressures appear to derive lasting benefits from a shunt that diverts ...
BOSTON, MA—One-year outcomes from an early feasibility study (EFS) show durable improvements in symptoms and quality of life in symptomatic heart failure (HF) patients treated with a novel coronary ...
Edwards Lifesciences Corp. is currently conducting the ALT-FLOW II Trial, officially titled ‘A Randomized, Sham-controlled Clinical Trial for Evaluation of the Edwards APTURE Transcatheter Shunt ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Edwards Lifesciences Corp. is conducting ...
Tulsa's Oklahoma Heart Institute is participating in a new trial to help treat congestive heart failure. The ALT-FLOW II trial is currently enrolling up to 100 participants at sites in the United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results